pemazyre 13,5 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 13,5mg - inhibitori de protein-kinaza
pemazyre 13,5 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 13,5mg - inhibitori de protein-kinaza
pemazyre 4,5 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 4,5mg - inhibitori de protein-kinaza
pemazyre 9 mg
incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 9mg - inhibitori de protein-kinaza
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - agenți antineoplazici - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
alunbrig 180 mg
takeda austria gmbh - austria - brigatinibum - compr. film. - 180mg - inhibitori de protein-kinaza
alunbrig 30 mg
takeda austria gmbh - austria - brigatinibum - compr. film. - 30mg - inhibitori de protein-kinaza
alunbrig 90 mg
takeda austria gmbh - austria - brigatinibum - compr. film. - 90mg - inhibitori de protein-kinaza
alunbrig 90 mg+180 mg
takeda austria gmbh - austria - brigatinibum - compr. film. - inhibitori de protein-kinaza